Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Marinus Pharmaceuticals Inc    MRNS

MARINUS PHARMACEUTICALS INC (MRNS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
8.14(c) 7.88(c) 7.9(c) 7.85(c) 8.07(c) Last
423 913 422 937 244 175 475 745 706 838 Volume
+4.49% -3.19% +0.25% -0.63% +2.80% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -31,0 M
Net income 2018 -30,6 M
Finance 2018 58,4 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -51,4 M
Net income 2019 -50,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 320 M
More Financials
Company
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics.Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous,... 
Sector
Pharmaceuticals
Calendar
08/07Earnings Release
More about the company
Surperformance© ratings of Marinus Pharmaceuticals In
Trading Rating : Investor Rating : -
More Ratings
Latest news on MARINUS PHARMACEUTICALS IN
07/16Free Technical Research on Marinus Pharma and Three More Biotech Equities
AC
06/26MARINUS PHARMACEUTICALS : to Be Added to the Russell 2000 and Russell 3000 Index
AQ
06/26MARINUS PHARMACEUTICALS : Initiates Pivotal Phase 3 trial in Children with CDKL5..
AQ
06/22MARINUS PHARMACEUTICALS : to Be Added to the Russell 2000 and Russell 3000 Index
AQ
06/21Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Inde..
GL
06/20MARINUS PHARMACEUTICALS : Initiates Pivotal Phase 3 Trial in Children with CDKL5..
AQ
06/19MARINUS PHARMACEUTICALS : Initiates Pivotal Phase 3 Trial in Children with CDKL5..
AQ
06/15Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule..
GL
05/31MARINUS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
AQ
05/30Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
GL
More news
Sector news : Pharmaceuticals - NEC
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/19$RDGL OMG seriously R U SEEING THESE BUYS?! WOW ?? $AAPL $MSFT $NOK $SNAP $A.. 
07/19$RDGL OMG DID U JUST C 2 MILLION BOUGHT ON ASK! ?? $AAPL $MSFT $NOK $SNAP $A.. 
07/18Want automatic email alerts for $MRNS $CUBI $MNK $PE $SALT? Subscribe to Mark.. 
07/18$PPBC GRANTED CANCER PATENT BY EU. UNKNOWN BLOODIED w\only 38 mil O\S @ .033.. 
07/17$PPBC GRANTED CANCER PATENT BY EU. UNKNOWN BLOODIED w\only 38 mil O\S @ .038.. 
More tweets
Qtime:58
News from SeekingAlpha
07/15WEEK 29 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
07/08WEEK 28 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
07/02Premarket analyst action - healthcare 
06/24WEEK 26 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
06/22After Hours Gainers / Losers (06/22/2018) 
Chart MARINUS PHARMACEUTICALS IN
Duration : Period :
Marinus Pharmaceuticals In Technical Analysis Chart | MRNS | US56854Q1013 | 4-Traders
Technical analysis trends MARINUS PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 $
Spread / Average Target 123%
EPS Revisions
Managers
NameTitle
Christopher Michael Cashman Chairman, President & Chief Executive Officer
Edward F. Smith Chief Financial Officer, Secretary, Treasurer & VP
Jaakko Lappalainen Vice President-Clinical Development
Lorianne K. Masuoka Chief Medical Officer
Nicole Vitullo Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MARINUS PHARMACEUTICALS INC-1.10%320
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225